QuVa Pharma is a nationally recognized company emerging as the leading industry 503B platform and partner of choice for compliance-oriented healthcare facilities looking to ensure a quality, safe and consistent supply of medications. The Company offers a broad portfolio of products across Pain Management, Anti-infective, OR Syringes, Labor and Delivery therapeutic areas amongst others, all of which are released only once sterility and potency testing is successfully complete, and with validation supporting appropriate BUD. The company is committed to having a patient-first orientation, as well as a robust product portfolio, leading safety standards, and collaborative, partnership-oriented customer service.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/31/18 | $15,000,000 |
Bain Capital | undisclosed | |
| 05/06/21 | $275,000,000 | Debt Financing |
Goldman Sachs Owl Rock Capital Partners | undisclosed |
